### Edgar Filing: NAVIDEA BIOPHARMACEUTICALS, INC. - Form 3

#### NAVIDEA BIOPHARMACEUTICALS, INC.

Form 3

October 15, 2014

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

**OMB APPROVAL** 

**OMB** Number:

3235-0104

Expires:

January 31, 2005

0.5

Estimated average burden hours per

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES** 

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, response... Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting

Person \*

A Gonzalez Ricardo J

(Last)

(First)

(Middle)

Statement

(Month/Day/Year)

10/13/2014

2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol

NAVIDEA BIOPHARMACEUTICALS, INC. [NAVB]

4. Relationship of Reporting

Person(s) to Issuer

(Check all applicable)

Chief Executive Officer

5. If Amendment, Date Original

Filed(Month/Day/Year)

5600 BLAZER

PARKWAY, Â SUITE 200

(Street)

Director

\_X\_\_ Officer

10% Owner Other (give title below) (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line) \_X\_ Form filed by One Reporting

Person

Form filed by More than One

Reporting Person

DUBLIN, OHÂ US 43017

(City) (State) (Zip)

1. Title of Security (Instr. 4)

2. Amount of Securities

Beneficially Owned (Instr. 4)

Ownership Form:

Table I - Non-Derivative Securities Beneficially Owned

4. Nature of Indirect Beneficial Ownership (Instr. 5)

Direct (D) or Indirect (I) (Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Date

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative 2. Date Exercisable and 3. Title and Amount of 5. 6. Nature of 4. Security **Expiration Date** Securities Underlying Conversion Ownership Indirect Beneficial (Month/Day/Year) Form of (Instr. 4) Derivative Security or Exercise Ownership Price of Derivative (Instr. 5) (Instr. 4) Security: Derivative Date Exercisable Expiration Title Amount or Security Direct (D)

Number of or Indirect Shares

(I)

1

### Edgar Filing: NAVIDEA BIOPHARMACEUTICALS, INC. - Form 3

						(IIIsu. 3)	
Inducement Stock Option	10/13/2015	10/13/2024	Common Stock	300,000	\$ 1.26	D	Â
Inducement Stock Option	10/13/2016(1)	10/13/2024	Common Stock	300,000	\$ 1.26	D	Â
Inducement Stock Option	10/13/2017(2)	10/13/2024	Common Stock	400,000	\$ 1.26	D	Â

## **Reporting Owners**

Reporting Owner Name / Address	Relationships					
1 0	Director	10% Owner	Officer	Other		
Gonzalez Ricardo J 5600 BLAZER PARKWAY SUITE 200 DUBLIN, OH US 43017	Â	Â	Chief Executive Officer	Â		

# **Signatures**

William J. Kelly,
Attorney-in-Fact

\*\*Signature of Reporting Person

Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Will not be exercisable unless and until the average closing price per share of the common stock for the ten trading days prior to exercise equals or exceeds \$2.50 per share.
- (2) Will not be exercisable unless and until the average closing price per share of the common stock for the ten trading days prior to exercise equals or exceeds \$3.50 per share.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2